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Cystic Fibrosis (CF), with an incidence of approximately 1 
l 2 • 
in 2000" and a gene carrier rate of between 3 and 5 percent, is 
the most frequently occurring lethal hereditary disease of 
Caucasians in this country* Rare among non-Whites* the CF gene 
is five times more common in the general U„S„ population than 
the gene for the next most frequent lethal hereditary disease, 
sickle cell anemia* 
While a definitive method for diagnosis of the disease, the 
sweat test, has been available since 1953,^ there has existed no 
such method for reliably identifying those heterozygous for the 
g 
CF Gene. In March, 1975, Chandra et al,, described a study m 
which, by radioimmunoassay, they were able to detect differences in 
the levels of serum Alpha^-Fetoprotein (AFP) between normals, those 
heterozygous for the CF Gene, and those homozygous for the same 
Gene. This, if reliably reproducible, would present a means for 
early identification of those at risk for producing a child with 
CF, and would provide the opportunity for adequate genetic 
counselling. Because of this, our interest in this means of 
heterozygote identification was greatly aroused and so we 
attempted in this study to determine if the population of hetero¬ 
zygotes having contact with Yale-New Haven Hospital (YNHH) could be 
similarly identified 

REVIEW OF THE LITERATURE 
Cystic Fibrosis 
Cystic Fibrosis is a truly protean disease® classically 
presenting with the triad of chronic pulmonary diseases pan- 
creatic insufficiency and abnormally elevated sweat electrolytess 
but frequently manifested as well by such entities as hepatic 
cirrhosis, rectal prolapse, intestinal obstruction, and nasal 
polyps. Meconium ileus, virtually pathognomic of CF, is present at 
birth in 10-15% of children with the disease^ and is often 
complicated by meconium peritonitis, volvulus, and/or atresia. 
Patients beyond the newborn period may present with the 
syndrome of meconium ileus equivalent marked by intestinal 
obstruction due to tenacious impacted stools. 
If untreated, children with CF typically exhibit failure to 
thrive despite ravenous appetites, foul-smelling stools, and 
abdominal distension. Steatorrhea, due to the malabsorption 
caused by pancreatic insufficiency, can be quite severe, with 
2 
fecal fat content averaging 4-5 times normal.^ The children tend 
to be small, with below average body weights, and appear malnourished. 
Liposoluble vitamin deficiencies (especially Vitamins A and K) may 
occur. Early diagnosis and symptomatic therapy may promote normal 
growth rates and physical appearance. Despite the fact that symptoms 

may regress during the period of adolescence* puberty may be 
delayed.^ 
Because of the elevated levels of electrolytes found in the 
sweat of CF patients, hot weather presents the considerable threat 
of severe sodium depletion and vascular collapse. Chronic 
pulmonary disease is a prominent feature of CF, eventually develops 
in all patients, and is generally severe and progressive. Time 
of onset varies, but initial features usually include wheezing 
and dry, nonproductive couqh. Atalectasis is not uncommon, and 
in some instances may present as the first manifestation of the 
O 
disease. Mucoid impaction of the bronchi presents as one of the 
most common complications. Episodes of pneumonia are frequent in 
some patients with Staph loco ecus aureus and Pseudomo nas aeruginosa 
(probably secondary to antibiotic therapy) being the most common 
9 
infecting organisms.' As pulmonary involvement becomes chronic 
and symptoms progress, chronic productive cough, wheezing and 
tachypnea, and cor pulmonale may become severe. Pulmonary 
function tests show decreased vital capacity and an increase in 
airway resistance proportional to the severity of the obstructive 
disease. Barrel-chest deformity and digital clubbing are common. 
The most common cause of death is acute respiratory distress 
# r\ 
resulting from pneumonia and anoxia. The liver involvement in 
CF occurs in approximately 2% of cases. These patients, most 
commonly in their teens, develop clinical liver cirrhosis (pathologi¬ 
cally focal bilary cirrhosis).'1'0 Increased consistency of the organ 
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and a nodular surface are noted. Elevations of serum ceruloplasmin* 
low serum cholinesterase* elevated alkaline phosphatase, and 
8 
abnormal BSP retention are confirmatory tests of this complication. 
Patients dying early in life commonly show small scattered areas 
of hepatic abnormality at autopsy. Plugs of inspissated material 
are seen in some of the small bile ducts, suggestive of stagnation 
of secretions. Early fibrosis around the distended ducts and 
biliary ductule multiplication in the portal tract may be present.^ 
Patients with cirrhosis may develop portal hypertension, hyper™ 
splenism, and bleeding esophageal varices. 
While the clinical manifestations of CF may vary, it seems 
clear that the disease is transmitted as an autosomal recessive 
trait.In addition, Danks et al.-^ suggests that it is quite 
likely that the disease may be caused by a single mutant allele at 
the locus concerned. There currently exists no adequate explanation 
for the high carrier frequency for CF observed in the Caucasian 
population. A high mutation rate, unlike that observed for other 
recessive traits, would be required in order to maintain the 
2 
observed incidence by mutation alone. In attempting to explain 
I O 
this, Anderson et al« have postulated a heterozygote advantage 
of increased fertility of female CF carriers. While such an 
advantage is quite possible, McCombs describes it to have been 
calculated to be about 2% and therefore difficult to detect. 
Several theories exist as to the pathogenesis of CF, each 
attempting to explain the myriad of symptoms characteristic of 
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the disease in terms of a single basic defect. These theories have 
been well described by numerous authors.lslls^^ Among the 
most popularly accepted are four which attribute the basic 
pathogenesis of CF to ion transport dysfunction, abnormal secretions, 
autonomic dysfunction, and abnormal serum factors respectively. 
The abnormally elevated level of sodium and chloride (and to 
some extent potassium) in the sweat of CF patients stands as the 
most constant feature of the disease,-'0 and. as such lends great 
reliability to the sweat test used for its diagnosis. The reason 
for these observed elevations, however, remains obscure. CF is 
marked by no morphologic differences in sweat glands,rates of 
] 8 
sweating, ' or in the concentration of the organic constituents 
19 20 
of sweat. ' Schulz, however, demonstrated by micropuncture 
techniques a failure in the reabserption of sodium from the fluid 
pi 
secreted into the sweat gland duct. Mangos, on the basis of 
microperfusion studies, concluded that this failure in reabsorption 
was due to an inhibitory effect exerted intraluminally by the sweat 
22 
of affected persons. In 1967, Mangos and McSherry isolated a 
nondialyzable heat labile factor from CF sweat and saliva which 
inhibited sodium reabsorption in the parotid gland of rats and 
in the normal sweat gland.The sweat glands in CF appear to be 
less sensitive than normal to the effects of salt-retaining steroids.15 
Balfe et al.24 examined active transport of sodium in the 
erythrocytes of CF patients. They reported both sodium pumps I and 
II to be decreased in activity in the red cells of children with CF. 
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While pump I appeared normal in parents of CF patients* th as 
a notable decrease in pump II (ethacrynic acid-sensitive) ivity 
in their red cells as compared with those of normal controls. Other 
investigators have* however* been unable to support these observations 
Gibson et al.^ have attempted to explain the basic defect 
of CF in terms of the abnormally high calcium content observed in 
all glycoprotein-rich secretions in CF (e.g.fl those elaborated by 
exocrine glands). Calcium levels in these secretions are elevated 
despite the presence of normal serum calcium* phosphorous*and 
probably sweat calcium levels.'"'7 Gibson et al.26 report the 
presence of a factor in CF serum which produces calcium hyper¬ 
secretion* while Horton et al.,28 based on their findings of 
reduced calcium-dependent red cell ATP-ase in CF erythrocyte ghosts* 
propose a defective resorptive mechanism as the reason for calcium 
elevations. Hadden et al.,25 however* failed to demonstrate a 
defect in CF patients of the calcium active transport system* which 
requires calcium-dependent ATP-ase. Another source-*-^ attributed the 
high concentrations of calcium in exocrine secretions to the 
inclusion of excessive amounts of calcium in secretory granules. 
Gibson^0 suggests that excess calcium secretion by exocrine glands 
results in the hyperpermeability of mucus which is therefore unable 
to inhibit the passive flow of water and small ions. This would 
result in the elaboration of abnormally highly concentrated and 
hyperviscous secretions which Johansen et al.^ claim might result 
25 
in direct tissue damage and duct obstruction, eventually leading to 
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the glandular lesions (lungs, pancreas* livers intestine) 
characteristic of CF. Di Sant'Agnese1 has alternatively suggested 
that this hyperviscosity might be due to the formation of a calcium- 
glycoprotein complex. Glycoprotein quantities in CF secretory glands 
are said to be normal, but they have been shown to have an 
29 90 
abnormal composition with an increased fucose to sialic acid ratio.^5" 
Saliva elaborated by the submaxillary gland in CF is rich in 
31 29 
glycoproteins and abnormal in its make-up and appearance. * 
CF saliva contains elevated amounts of calcium, fucose, sialic 
acid, hexose, and total protein. ^ It is turbid in appearance, but 
can be cleared to resemble normal saliva by the addition of 
chealating agents. The addition of calcium to normal saliva results 
in increased turbidity.^2 as j[n sweat, sodium and chloride concentra¬ 
tions have been noted to be elevated in CF saliva,^3 
In 1959, Roberts^ postulated that the basic defect in CF 
might be due to a chronic excess ox parasympathetic stimulation of 
the body’s cholinergic glands, including Brunner’s glands, sweat 
glands, pancreatic, bronchial, and salivary glands. The histologic 
changes seen in the disease were, he proposed, due to the exhaustion 
of these glands. This hypothesis has long been a popular one since 
the autonomic nervous system innervates and controls the secretory 
function of the very same exocrine glands which are most notably 
affected in CF. Chernick et al.31 demonstrated that parasympathomimetic 
stimulation in normal children (but not in adults) resulted in the 
production by them of saliva similar in composition and appearance to 
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that of CF patients. They also showed that CF saliva became 
clear and normal in the concentrations of its constituents (except 
for calcium which remained elevated) after injection with the 
adrenergic blocking agent* guanethidine,00 An examination of the 
adrenal medullas of CF patients at autopsy has revealed the presence 
of elevated levels of catecholamines.''0 The observation of 
elevated urinary Catecholamine metabolites in CF was made in 
1967 (as recorded by di Sant{Agnese^) * but others found these 
0*7 OQ 
levels to be normal. Rubin et al. concluded that a generalized 
autonomic dysfunction existed in CF on the basis of differences 
they observed between the pupillary reactivity of individuals with 
CF and normals under conditions of rest and stress* and after 
termination of painful stimuli. They concluded that the CF patient 
suffered from adrenergic underactivity. Spock,^ however, suggests 
that rather than being a generalized autonomic disturbance, the 
site of such a defect in CF would more likely be at the 
neuroeffector junction or within the affected secretory gland 
• • • QO 
itself. Working on isolated dog salivary glands, Dische et al. 
reported an alteration in glycoprotein composition reminiscent 
of that seen in CF (increase in fucose and decrease in sialic 
acid) after pilocarpine stimulation. On the other hand, chronic 
pilocarpine^50 or atropine^ stimulation has failed to reproduce the 
CF complex in experimental animals. An attempt to alleviate or 
reverse symptoms in CF patients by sympathetic blockade with 
cocaine, followed by a right-s.ided complete splanchnicectomy 
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has proved ineffective.42 
43 
Spock et al. demonstrated in 1967 the presence of a heat 
labile, nondialyzable factor in the sera of children with CF which 
disorganized the regular ciliary rhythm in rabbit tracheal explants. 
This ciliary dyskinesia factor (CDF), was detected in the sera of 
obligate heterozygotes for the CF Gene, though in lower concentrat.ion* 
While initially encouraging as a possible means for heterozygote 
detection, this technique is based on a subjective judgment and has 
proved unreliable, as normal sera have been observed to produce the 
CDF effect.44 In 1969, Bowman et al.4^ introduced a modification 
of Spock*s technique which employed oyster gill cilia in place of 
rabbit tracheal explants, and which was more quantitative in that 
the time required for cessation of all ciliary motion was the 
recorded value for each serum tested. The group found CDF effects 
in the same settings as did Spock. The bulk of the work which 
has been done on CDF has employed the oyster gill technique since the 
time of its introduction. Much work has been done in attempting to 
46 
determine the exact identity of CDF. In 1970, Bowman et al. 
determined that CDF migrates in they-globulin fraction of serum, 
raising the possibility that it might be a specific antibody. 
Herzberg et al.,4^ however, determined that while associated with 
the IgG fraction, CDF does not interact with oyster cilia in a 
typical antigen-antibody reaction. Danes et al. have provided 
evidence to show that CDF is probably simply bound to certain 
49 
Y-globulins. It was shown in 1972 that the CDF effect could be 
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produced by the medium from in vitro cultures of skin fibroblasts 
from those with CFS but not by fibroblast from normal individuals® 
Conover et al.50 have presented evidence that anaphylotoxin (C3a) 
is a pre-CDF which, both at the cell surface and bound to IgG 
(C3a~IgG complex is CDF), is the prime mediator of the various 
pathophysiologic conditions seen in CF. They suggest that C-3a may 
act at the secretory cell surface to facilitate extrusion of granules 
or other materials reflecting the cell’s function (e«g», digestive 
enzymes from salivary cells). This secretion, rapidly terminated in 
the normal state by a degradative enzyme (anaphylotoxin inhibitor), 
would continue if such enzyme were deficient or absent, resulting 
in the accumulation or secretory products leading to the classic 
picture of organ involvement seen in CF» Thus, they suggest a 
defect in or deficiency of anaphylotoxin inhibitor would be the 
primary defect in cystic fibrosis. Polley and Bearn^l in 1971 
also suggested the possible relation of CDF to the complement 
system. While this appears as one of the more promising 
developments in the research on CDF, factors such as the lack of 
clear definition of CDF as central to the pathogenesis of CF, or 
byproduct of the disease; the report by Wood and di Sant’ Agnese'"' 
suggesting that CDF activity may be present in normal serum even 
with the oyster assay; and the alternate claim of identification of 
CDF as amylase by Doggett et al., * must be resolved. 
Another long recognized defect in CF is the observation made 
by Mangos and McSherry^2 that sweat and saliva from affected 
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individuals markedly inhibit the reabsorption of sodium when 
infused into rat parotid ducts. Whether the factor responsible 
for this effect and CDF are the same is not known. Murakami and 
Eckert^b have shown that the regulars well coordinated beating of 
cilia is dependent on normal calcium transport across cell membranes 
It is indeed possible that the CDF may produce its effect by causing 
abnormal calcium flux or abnormal calcium secretion by exocrine 
glands as Gibson postulated.^ Spock et al.^ speculated that the 
serum factor he described might alter the transport of electrolytes* 
thereby producing changes in the action potential within the cell 
and resulting in the observed ciliary dyskinesia. Mangos and 
op 
McSherry, observing that positively charged molecules acted in 
the same way as their CF factor to inhibit sodium transport in the 
parotids of rats, suggested that this factor might be such a 
positively charged molecule, whose effect was the result of an 
alteration in membrane permeability. Interested in this possibility 
they added heparin, a negatively charged molecule which has been 
shown to form complexes with positively charged molecules, to the 
sera of individuals with CF. Upon doing so they noted an apparent 
negation of the inhibitory effects originally exhibited by these 
sera. CDF has been shown to bear a positive charge.^ and Bowman 
et al. observed that positively charged molecules, other than 
CDF, could produce the same effect on oyster cilia. Finally, 
Doggett et al.'JO»^M,'J demonstrated that heparin could reverse the 
dyskinetic effects of CF serum and saliva upon oyster cilia, both 
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in vivo and in vitro. 
Danes and Bearn^0 have demonstrated that fibroblasts of CF 
patients contain an abnormal cytoplasmic substance which causes them 
to stain metachrornatically. They also noted that the fibroblasts 
of heterozygous relatives showed the same metachromasia which was 
absent from the stained fibroblasts of normal subjects. Two 
different patterns of metachromatic staining were identified. These 
are genetically consistent (CF patients and parents always show the 
same type) and may therefore be demonstrating heterogeneity of 
the CF locus. The observed staining is thought to represent 
accumulated acid mucopolysaccharides whose presence, Spock^ has 
speculated, may be due to a cell membrane defect, a defect in th 
lysozymes or a specific enzyme within the lysozyme which normal], 
breaks down mucopolysaccharides, or an increased synthesis due to 
lack of an inhibitor. The exact significance of the observed 
staining characteristics of CF fibroblasts remains uncertain. 
With regard to heterozygote detection, the only test available 
in the recent past upon which to base genetic counseling of those 
at risk has been the oyster gill bioassay for CDF. This test, 
however, by the condemnation of those rejecting it, and the 
admission of some ox those employing itf^ is unreliable and 
subject to inherent variability due to the fact that it is a 
bioassay. It can also be expensive and difficult to set up--all in 
all unsuitable for mass screening for detection of heterozygotes. 
In attempting to isolate and identify CDF by an alternate means. 
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Atland et al.59 employed isoelectric focusing and disc electro¬ 
phoresis. They were successful in isolating a factor from the serum 
of CF patients and obligate heterozygotes which they felt to be 
similar to, if not identical with, CDF. Wilson and Fudenberg^ 
also employed isoelectric focusing to obtain similar results in 
successfully identifying CF homozygotes and heterozygotes. 
Swachman et al.^ were able to distinguish all homozygotes and 
90% of the heterozygotes in their study from normal subjects. 
They did this by utilizing the Ussing chamber technique to 
measure differences in the electrical properties (potential 
difference and resistance) of rat jejunum in the presence of the 
sera to be tested. Finally, as mentioned in the introduction, 
Chandra et al.^ have described the ability to distinguish CF patients 
and obligate heterozygotes from normal subjects on the basis of 
their serum Alpha^-fetoprotein levels. This work, forming the basis 
for the current study, will be more fully discussed in the next 
section of this paper ("Alpha^Fetoprotein"). 
What occurs, then, from a review of the evidence for each of 
the four major theories of CF pathogenesis is a multiplicity of 
results, some positive, some negative, from which no clear cut 
conclusions can as yet be drawn. The pleiotropic effects of the CF 
Gene will continue to mask the identity of the basic defect in this 
very common disease until we are able to develop a better working 
knowledge of the basic principles behind the pathologic features of 
each of the systems involved. Only then can we hope to recognize the 
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set of generalised principles at work in all of these systems which 
produces the entity we call cystic fibrosis. 
Alpha^-Fetoprotein (AFP) 
In the progression from fetus to adult, there is presumably a 
complex sequence of biochemical "on-off" switches which controls 
the normal pattern of growth. It is possible that the relatively 
uninhibited growth of malignant cells is somehow representative of 
a de-differentiation process causing the cells to revert to embryonic 
growth patterns. The first immunological evidence that embryonic 
phase-specific antigens (PSA) might be related to tumor antigens 
appeared in 1932 and, since that time, numerous investigators 
60,66,67,62,63,64 ^ave examinec] this possibility. Among the more 
intriguing and useful applications of this concept has been the 
measurement of elevated levels of embryonic PSA in adults, and the 
use of such measurement both to. indicate the presence of neoplastic 
disease and to monitor its course and response to treatment. In 
recent years, the presence of elevated levels of a protein which 
normally occurs in the sera of human fetuses (variously known as 
fetoprotein, postalbumin, <=<^"fetoprotein, and ^-globulin) has been 
demonstrated in a large number of patients with primary tumors of 
the liver or with teratoblastomas. Its reappearance in large 
quantity in the serum of adults has resulted in the generali2ed 
acceptance of AFP measurement as a diagnostic test for the presence 
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r ,, •, 67,68 
of these neoplasms. * 
AFP was first identified by Pedersen in 1944^ in sera from 
the newborn calf and was named "fetuin" at that time. After 
detecting a trace of AFP in human cord blood, Bergstrand and 
70 
Czar extended this observation and later reported the detection 
71 79 
of AFP in the serum of human fetuses less than 5 months old. 9 
The new protein was found to migrate between albumin and ^-globulin 
on paper electrophoresis. It was further established to have a 
molecular weight between 64000^ and 70000^*^ and to be formed 
by a single polypeptide chain.7Ss74 Reliable detection and measurement 
initially presented formidable technical problems, ° but with the 
development of more sophisticated immunological techniques 72s^7 
these problems were overcome, setting the scene for more detailed 
inquiries. A summary of immunological techniques for AFP detection, 
along with their sensitivities and applications is provided in 
Table I from Adinolfi et al."^° 
TABLE I 
SOME IMMUNOLOGICAL METHODS TOR THE 
DETECTION AND ESTIMATION OF AFP* 
Methods | Scnsitivityf Application 
Double diffusion in 1 2-5 r^g/ml Detection 
agar gel i 
Counter-current 0.25-0.5 ug/ml Detection; 
electrophoresis 1 semi-quantitative 
Single radial diffusion 2.5 Mc/ml Quantitative 
Electroimmunod illusion 0.5-1.0 nc ml Quantitative 
(rocket) | (50 r.g ml4 
Radioimmunoassay 2-5 nq ml Quantitative 
Enzyme-lmked 1 5 ng,mi i Quantitative 
immunoassay { j 
Reverse agglutination 5 ng/ml Quantitative 
• For references see text. 
■f Lowest sensitivity using conventional technique. 
t The sensitivity is increased using an immunoradioassay or an im- 
munoperoxidase lest. 
(Adinolfi, A., et al., Alpha-feto-protein during development 
and in disease. J. Med. Gen., 12:138-151, 1975.) 
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Recent results with radioimmunoassays for AFP have demonstrated 
even greater sensitivities than those quoted by Adinolfi* with 
Ruoslahti and Seppala74 reporting a sensitivity threshold of 
250 picograms per milliliter. Other workers have reported 
sensitivities down to 165 ng/ml for the single radial diffusion 
technique. Sizaret^8 has utilized the technique of radioelectro- 
complexing (a radioimmunoassay which employs electric current first 
to bring together the immunoreagentss and then to separate the 
bound from the unbound radiolabelled antigen) to reach sensitivities 
between 200 and 400 picograms per milliliter of AFP. 
By means of the immunodiffusion techniques* it has been 
established that AFP is normally present in human fetal serum* 
making its appearance in measurable quantities by the 4th week of 
development. The levels of the protein rise steadily over the next 
1- 3 months* reaching their peak values of 200-400 milligrams per 
100 milliliters by 12 to 16 weeks of gestation.'/7j ^ At this time 
AFP may comprise one-tenth of the total fetal proteins.74 Beyond this 
period* AFP levels fall rapidly* until at birth concentrations of 
2- 17 milligrams per 100 milliliters77*^ or less88 are present. In 
the period immediately after birth, this level decreases (T’P = 3-5 days8^) 
to levels detectable only by radioimmunoassay. Any form of acute 
liver disease during this period of neonatal decrease can result 
m transient elevations of serum AFP. Increased levels of serum 
AFP (44-2800 micrograms/milliliter) were found in children with 




other immune deficiency diseases. The persistence of high AFP 
levels in these patients is associated with the hypothesis that 
the primary defect is an abnormality of tissue differentiation. 
The generally accepted range of AFP levels measurable in normal 
subjects by radioimmunoassay is 1-25 ng/mls although levels 
as high as 50 ng/ml have been reported in apparently normal 
subjects free from detectable disease. 
Noting the decrease in fetal serum AFP levels during the last 
trimester, Bergstrand et al.^2 have attempted to correlate AFP 
levels with fetal maturity. Their results indicated that AFP levels 
in premature infants' sera were generally higher than those in 
full"term infants. They also found AFP levels to be more closely 
correlated with gestational age than either birth weight* total 
serum protein level* or serum albumin, 
SeppSlS and Ruoslahti-1 also found a correlation between 
amniotic fluid AFP levels and gestational age* with AFP levels 
decreasing with advancing gestation during the last trimester. 
By employing radioimmunoassay* these experimenters were able to 
detect AFP in amniotic fluid of normal fetuses from all three 
trimesters. Prior to this* immunodiffusion techniques had only 
been able to detect amniotic AFP during the first 22 weeks of 
gestation. ^ Amniotic AFP levels decreased from levels of 2600- 
2800 nanograms per milliliter during the second trimester* to 
levels of 15-535 nanograms per milliliter during the third 
trimester. AFP is known to be produced by the fetal liver and 
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yolk sac.^ Sepp^lS and Ruoslahti83 have suggested that the high 
amniotic component of AFP seen early in gestation may be derived 
from urinary AFP. This suggestion was made on the basis of 
their measurements of early fetal urinary and amniotic AFP as well as 
their observations of elevated amniotic AFP in the case of fetuses 
with congenital nephrosis. 
Abnormally elevated amniotic AFP levels have been used at, 
various times of gestation as a marker for an affected fetuso Thuss 
between 18 and 36 weeks of gestation, elevated amniotic AFP levels 
have been correlated with and successfully diagnosed anencephaly 
and spina bifida in utero.Seller and Adinolfi^ have suggested 
that the high levels of amniotic AFP in the case of open neural-tube 
defects is due to the transfer of AFP from the CSF. They detected 
AFP levels of 52 to 1220 micrograms per milliliter in the CSF of 
normal fetuses from 16 to 25 weeks of gestation. In a prospective 
OCA 
study, Harris et al. concluded that most cases of spina bifida 
and anencephaly were detectable by a combination of amniotic AFP 
measurement and ultrasound before 20 weeks of gestation, providing 
the opportunity for selective abortion. They found closed neural-tube 
defects to be associated with normal amniotic AFP levels while open 
neural-tube defects showed low AFP levels if measured during the 
last trimester when only a small amount of the protein is synthesized 
by the fetus. 
87 
SeppaiM noted elevated AFP levels in both amniotic fluid 




et al. have suggested that these elevations may be due to 
transendation of AFP in the amniotic fluid and transfer of the protein 
across the placenta associated with fetal death. This mechanism 
may also explain elevated maternal serum AFP levels which have 
been noted in the event of severe distress.^ Elevated amniotic 
AFP levels in cases of severe Rh incompatability have been attributed 
to increased synthesis of AFP.°ys^° 
Hirose*^ has well summarized the implication of abnormally high 
AFP levels in pregnancy. 
(1) fetal malformation: when maternal serum-AFP 
level is within the normal range but the amniotic 
fluid AFP concentration is markedly elevated; (2) 
placental dysfunction: when the maternal AFP 
level is markedly elevated irrespective of the level 
of AFP in amniotic fluid; and (3) placental 
dysfunction combined with fetal malformation: when 
both maternal serum-and amniotic-AFP levels are 
extraordinarily elevated. 
QO 
SeppSlS and Ruoslahti have reported* by measurement with 
radioimmunoassay* high levels of AFP in maternal sera throughout 
pregnancy. They found levels of 18-119 nanograrns per milliliter 
during the first trimester* 96-302 nanograms per milliliter during 
the second trimester, and 160-550 nanograms per milliliter during 
the third trimester. At labor these levels were between 103 and 
400 nanograms per milliliter. The facts that the maternal and 
fetal serum AFP levels were significantly correlated (the highest 
maternal AFP levels were measured in those whose fetuses had highest 
levels, though maternal peak levels lagged behind fetal peak levels) 
and that maternal AFP levels fell rapidly during the post partum 
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period (TS’ = 5 days as in infant) suggested to these investigators 
that the fetus is the source of maternal AFP elevation, Ihe 
alternative possibility that the hormonal changes of pregnancy 
might temporarily de-repress AFP synthesis was considered by 
no 
SeppSlcl.' ' This investigator found no rise in AFP following the 
hormonal changes induced by oral contraceptives, SeppSlS and 
Ruoslahti^ were unable to demonstrate the presence of maternal 
antibodies to AFP, The mean levels of maternal serum AFP have been 
93 
found to be higher for multiple pregnancies than for single ones/ 
The exact biological function of AFP in humans remains unknown, 
OA 
Uriel et al,y found that the hormones estrones estradiols estriol* 
and diethylstilbestrol are bound by AFP in the rats and suggest 
that AFP may play a role in hormonal transport and in the feto- 
maternal relationship across the placental barrier in this animal. 
The fact that estrogen binding in humans is known to be associated 
with albumin and a P-globulin and the fact that Swarty et al.^° 
were unable to demonstrate estrogen-binding by human AFP suggest 
that AFP probably plays a different role in man. Observations 
on the part of Murgita and Tomasi on the effects of AFP on 
1° and 2° antibody responses in mice has led them to suggest a 
possible immunoregulatory function for AFP, They postulate 
that AFP may in normal development protect the fetal mouse against 
immunologic attack by the mother. Again these results are not 
necessarily applicable to humans, 
Abelev et al. first reported that transplantable mouse 
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hepatomas synthesized and secreted into the blood anet-globulin 
immune logically identical to AFP* in 1963. In 196d* Tatarinov 
extended this observation to human patients with hepatocellular 
carcinomaSince that time* numerous studies examining the 
relationship between AFP., hepatoma, and liver disease in general 
, , 80,98.99*100 
have appeared. 3 3 s 
Employing double-gel diffusion, AFP is detectable in the sera 
of some 30% of Caucasian hepatoma patients in the U.S.^ This 
figure is increased to between 50%^® and 60%-^- of Caucasian 
hepatoma patients aid a higher percentage of other racial groups 
if the more sensitive counterelectrophoresis and electroimmunodiffusion 
techniques are employed. Between 75% and 90% of hepatoma patients 
1 f)9 
in Africa have been found to be AFP-positive by these techniques. 
1 03 
In addition to geographic variations* Bagshawe and Parker' have 
observed variation in the detectability of AFP in the sera of 
hepatoma patients of the same ethnic background who differed in age. 
Elevated AFP levels were detected significantly more frequently 
in hepatoma patients less than 30 years of age than in those 
over 60. In view of these variations, it has been suggested that 
the fetal gene for AFP production may undergo reactivation in the 
adult more readily under the influence of certain genetic or 
etiological factors and at younger ages. ^ Abelev^4 has suggested 
that the findings of elevated AFP levels in apparently healthy 
adults from "high risk" regions (Senegal and Congo)105,106 may be 
the evidence of an enlarged initial pool of the "precursor cells" 
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(oval cells whose conversion into small hepatocytes during liver 
regeneration in the presence of carcinogens has been correlated with 
maximal AFP production)0r of an easiness of their activation*, 
This, he believes, might be a basic reason for the comparatively 
high frequency of primary hepatocellular carcinoma among certain 
human populations. 
Partial hepatectomy in humans has been reportedly associated 
with AFP synthesis,but such reports have been episodical 
and often contradictory.This has tended to support the 
conclusion that human AFP cannot be simply a product of regenerating 
68 104 
hepatocytes. Abelev has chosen to differentiate between the 
type of hepatic regeneration seen after hepatectomy and that 
observed during the acute phase of chemical carcinogenesis. 
Watabe^’ has demonstrated that AFP synthesis during the acute 
phase of chemical carcinogenesis in the liver takes the form of 
a steep wave which drops off until the actual appearance of 
hepatoma, but rises sharply again with tumor development. Abelev 
explains that the basic process of regeneration after hepatectomy 
involves proliferation of pre-existing hepatocytes as shown by 
112 
Leduc. During the poisoning of liver cells by a carcinogen and 
liver regeneration in its presence, however, new hepatocyte 
formation takes place from the precursor cells with complete renewal 
of the hepatocyte population. This basic difference, suggests 
Abelev, may well be the explanation for inconsistent findings of 
AFP synthesis after hepatectomy as compared to the well documented 
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AFP rise which accompanies chemical carcinogenesis. 
Abelev^*^ believes that his "precursor cells" are at 
greatest risk for undergoing tumor transformation and as such 
represent target cells for such transformation. He suggests that 
the initial action of a carcinogen is to be selectively toxic for 
mature differentiated hepatocytes and cause their degeneration. This 
results in proliferation of "precursor cells" as part of the 
regeneration process, and simultaneously increases the target 
cell population for tumor transformation. The actual transformation 
may be due to the action of an activated virus, a chemical 
carcinogen, or may be spontaneous, but a critical number of target 
"precursor cells" is certain to have been created by the action of 
the initial carcinogen. 
After surgical resection of the tumor mass in cases of 
hepatoma, elevated serum AFP levels have been observed to decrease 
temporarily,decrease to a steady level.or eventually 
78 
disappear. In cases of a decreased, but steadily maintained 
level, it has been suggested that this pattern may be due to 
incomplete removal of the tumor mass with viable cells continuing 
to elaborate AFP, but with a lower total production. Complete 
disappearance of AFP may indicate rejection of remaining tumor 
cells by a host cellular immune response, but is not generally 
70 
regarded as confident evidence of cure. 0 Reappearance of AFP or 
an increase in levels is generally regarded as evidence of recurrence 
of disease. Therapeutic regimens other than surgical resection 
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(i,e,, chemotherapy, radiotherapy) have generally been regarded 
as having little if any effect on altering AFP levels, 
There is no evidence that benign liver tumors (hamartomas, 
adenomas, hemangiomas) or bile duct carcinomas are associated with 
elevated serum AFP levels. Hepatic metastases from cancer of the 
stomach and from pancreatic adenocarcinomas have, however, been 
reported to have had accompanying elevations in serum AFP,J'^) 
With regard to the concept of de-differentiation and reversion 
to fetal growth patterns mentioned earlier, numerous authors 
have attempted to determine whether the AFP seen in the case of 
primary hepatocellular carcinoma is the same as that normally 
elaborated by the fetal liver. On the basis of analyses of 
*73 6 V 
physical and chemical properties, ° and immunologic properties. 4 
118,117,74 
it has generally been concluded that both normal fetal 
and cancerous liver cells produce alpha-fetoproteins which are 
structurally indistinguishable and probably identical. 
In addition to hepatocellular carcinoma, elevated AFP levels 
have also been demonstrated to be consistently associated with 
teratocarcinomas of the testis and ovary. This observation was 
independently and simultaneously made for the first time by 
ftf) 77 
Masopust et ai, and Abelev' in 1968. Both experimenters found 
the protein to be present by gel precipitation in approximately 
50% of untreated patients with highly undifferentiated tumors. 
Proceeding from the original observations cf Gitlin and Boesman-^8 
that the endoderm of the fetal yolk sac was capable of AFP synthesis. 
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as well as from the fact that structural analogues of the yolk 
sac are characteristic of teratoblastomas*Abelev^ suggested 
the elaboration of AFP by these tumors might be due to the presence 
in them of functioning yolk sac, Gitlin et al, also suggested 
that analogues of the endoderm of fetal yolk sac and primary gut 
present in teratocarcinomas could determine AFP production by them, 
1 o *i *1 <^9 
Work by Mawas et al, 1 and Engelhardt et al,"^ has provided direct 
confirmation of this hypothesis. 
Estimation of AFP levels in patients with teratoblastorna 
has essentially the same diagnostic and prognostic value as in the 
case of hepatoma. Detection of AFP by gel diffusion in the 
appropriate clinical setting can be considered virtually diagnostic 
of teratoblastorna or hepatic carcinoma, AFP levels can decrease to 
normal after surgical intervention as in the case of liver tumors* 
and reappearance of elevated levels carries the same ominous prognosis. 
Similar to the findings in the case of hepatic tumors.* Mawas 
et al.123 ^reported a relationship between age of the patient and 
the appearance of elevated AFP levels. High levels were found in 
56% of patients less than 15 years of age* but in only 15% of older 
patients. No elevation of AFP levels have been demonstrated in 
other childhood tumors such as neuroblastoma* nephroblastoma* 
osteosarcoma* embryonal carcinoma* various brain tumors* liver 
angioma, and lymphoreticulosarcoma.123 
The presence of elevated AFP levels in certain non-neoplastic 
liver diseases was first demonstrated by Alpert et al„y who 
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reported such elevations in patients with viral hepatitis. 
Since that time, transient elevations in AFP levels have been 
1ps I 04 
reported by others in cases of viral hepatitis* '* and 
197 194.196 qq 
alcoholic cirrhosis. * s" Abelev has shown that AFP levels 
rose between 15 and 30 days after the onset of viral hepatitis and 
returned to normal between 15 and 26 weeks thereafter, Chandra'*'00 
reported a higher percentage of AFP-positive sera in young hepatitis 
patients than in adult patients, Karvointzis and Redeker u note 
that the highest AFP levels are found in the most severe cases and 
that the appearance of AFP in the sera of patients in coma is 
followed by recovery. This may be due to the association of AFP 
synthesis with hepatic regeneration. 
The association between elevated AFP levels and chronic 
190 
liver disease was also reported by Belanger et al* ' These 
experimenters detected elevated AFP in the sera of eight patients 
with hereditary tyrosinemia. This inborn error of metabolism is 
associated with Fanconi's Syndrome* and in addition is marked by 
progressive degeneration and cirrhosis of the liver. It is 
characterized by an autosomal recessive pattern of inheritance. 
In cases of very early onset* hepatic symptoms predominate* and 
death from hepatic insufficiency may result during the early months 
of life. The development of malignant hepatoma may occur in those 
patients who survive long enough, and this may have some bearing 
on the presence of elevated AFP levels. 




Chandra et al. suggested in March 1975 that a strong correlation 
existed between elevated serum AFP levels and the presence of the 
CF Gene, Employing techniques of gel diffusion, counterimmunoelectro- 
phoresis, and radioimmunoassay, they measured the levels of AFP in the 
sera of 22 healthy controls, 18 children with CF, 16 parents of 
children with CF, 14 siblings of CF children, 7 patients with 
celiac disease, and 7 patients with bronchiactasis. AFP levels 
were found to be elevated in all CF patients (Range ~ 56-8825^g/l| 
Log mean = 690 - 1,18), 15 parents (Range = 25-568/<g/l; Log 
mean = 178 - 0,85), and 7 siblings (Range for all sibs = 6-400/^g/lj 
Log mean = 43 - 1,60; Range for elevated sibs = 75-400/^g/l), 
All others fell in the normal range of 5-25Ag/l, There was no 
overlap observed between the AFP levels in normal controls and 
in obligate heterozygotes (parents). No correlation between AFP 
level and severity of symptoms was found. The experimenters 
interpreted the bimodal distribution of values among siblings 
tested as reflecting those heterozygous for the gene (elevated 
values) and those who were not carriers. They suggest, on the basis 
of their results, that AFP be considered a marker for the CF Gene, and 
that serum AFP concentrations should be determined in all first- 
degree relatives of patients with CF in order to identify the 
carrier state. Acknowledging that the pathogenesis of liver 
involvement in CF is unclear, they suggest that the CF Gene 
may adversely affect normal processes of maturation in the 
fetus (especially in gut-associated tissues such as the liver) 
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resulting in the persistence of cell lines capable of synthesizing 
AFP and simultaneously making the liver more susceptible to damage 
such as fibrosis* cholestasis3 and multilobular cirrhosis. 
Since the time that the current study was begun* other 
investigators have considered the findings of Chandra's group in 
their own radioimmunoassay studies. Three British investigators s 
131,132 were unable to support the findings while an American expert- 
menter reportedly did* Wailwork et al. ° ; examined 37 CF children* 
24 of their parents* and 10 of their siblings and found AFP 
concentrations in all to be well within their normal limits 
1 n 1 
(25 ng/rnl) with a median value of 10 ng/ml. Brock et al. 
reported a similar normal range (3,4-18.0 ng/ml) and found that 
the seven CF patients tested fell well within it (2.0-9.25 ng/ml). 
Fitzsimmons et al.^2 examined 46 CF patients* 31 siblings, 80 
obligate heterozygotes (parents)* and 23 normal controls. This 
group’s findings are interesting in that they found a wider range 
of AFP values among controls (3-51 ng/ml; median = 9)* but they too 
found no difference between these values and those of the CF 
heterozygote and sibling groups (CF range = 1-44$ median = 11; 
Heterozygote range ~ 1-41; Median ~ 9; Sibling range = 1-55; median = 9). 
Smith’s' data* however, does support that of Chandra et al. He 
examined the sera of seven children with CF and found the mean AFP 
value to be 1825 ng/ml with a range of 130-2360 ng/ml. Fourteen 
parents had a mean of 433 (range = 80-1055) ng/ml and three out of 
eleven siblings showed AFP elevations (840, 1365, and 1980 ng/ml 

-29- 
respectively). The range for normals was not provided. 
These contradictory findings suggested the possibility that 
AFP levels might indeed be used as a marker for the CF Gene and 
confirmed the need for further work to resolve this important question. 

MATERIALS AND METHODS 
Subjects 
Members of the homozygote group were all outpatients of the 
YNHH CF Clinic who were having blood drawn for other tests® There 
were twenty-two subjects in this groups of whom fifteen were male 
and seven were female. Ages in this group ranged from 6 years 
to 24 years with a mean age of 13.6 years. Because of the 
] 34 
negative results of this study, Swachman scores ' which were to 
have been used to correlate CF severity with AFP levels were not 
determined. None of the subjects were malnourished or cyanotic, 
and all had normal liver function tests at the time that the 
specimens were obtained. Diagnosis of CF had been established by 
pilocarpine iontophoresis with sweat chlorides higher than oOmmol/l. 
Members of the heterozygote group included twenty male and 
thirty-three female parents of children seen in YNHH CF Clinic. All 
were in good health at the time the specimens were obtained., and 
all were without any history of chronic disease. Ages in this 
group ranged from 23 to 56 years with a mean age of 36.7, 
There were twenty members of the normal control group. These 
included five male and seven female children seen at the YNHH 
pediatric clinic for well child care who were having routine bloods 




male YNHH medical student and house staff volunteers* Ages in 
this group ranged from 2 to 34 years with a mean age of 16.1* 
All were in good health with no history of chronic disease. 
All subjects in the three groups were Caucasian. 
Collection of Specimens 
Specimens from Pediatric and CF Clinics were drawn into a 
plastic syringe from a clean venopuncture by using a #21 butterfly 
needle. The blood was then immediately placed in a red-topped 
glass Vacutainer test tubes refrigerated at 4°C9and allowed to 
clot. Specimens were then spun at 3000 rpm for 15 minutes. Serum 
was removed by Pasteur pipets aliquotted into 2cc bottles., labelleds 
and frozen at -20°C» Care was taken to thaw each specimen only 
oncea immediately prior to use. 
Isolation of AFP 
Purification of AFP was accomplished in essentially the manner 
described by Nishi'-3 and employed by Ruoslahti and SepphlS. Known 
rabbit antiserum to AFP (used by the YNHH Clinical Immunology Lab 
for AFP quantification) was combined with an AFP source (amniotic 
fluid and sera from legally aborted fetuses) after determination 
of the appropriate antigen-antibody ratio by a method of immuno- 
precipitation in capillary tubes. The antiserum-AFP mixture was 
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incubated at 37°C for one hour and then stored for fourteen hours 
at 4°C. The mixture was then spun at 3000rpm for 15 minuteso 
The supernatant was removed* saving the precipitate of antigen- 
antibody complexes- The immuno-precipitate was washed several 
times in normal saline and then dissolved in 0*1 M glycine/B31 (pH = 2) 
to disassociate the antigen-antibody complexes* Separation of free 
AFP from free antibody and antigen-antibody complexes was then accomplished 
by gel filtration on Sepnadex G-200. Glycine/HCl (0.05M) in normal 
saline (pH - 2) was used for elution and the collected fractions 
were brought to neutral pH (pH = 7,4) with appropriate amounts of 
0.2M Phosphate Buffer* 
This process was repeated several times as antisera more 
specific in their binding of AFP became available* resulting in 
purer isolates of AFP, In order to remove all possible contamination 
of AFP by components of normal human serum* a pellet was made by 
polymerizing rabbit anti-whole human serum with glutaraldehyde. 
The pellet was incubated with the AFP containing eluates for one 
hour at 37°C and then refrigerated at 4°C for 20 hours. The samples 
were then centrifuged at 3000rpm for 15 minutes and the AFP- 
containing supernatant was removed. Immunodiffusion by the Ouchterlony 
techniques showed lack of immunoprecipitation of purified AFP 
by rabbit anti-whole human serum* but a strong single line of 
precipitation by raboit anti-AFP indicating the purity of the 
preparation (Figure I), Immunoelectrophoresis also revealed 






Purity of Isolated AFP 
Figure I. Large well contains purified AFP. Small well contains 
specific anti AFP serum. Single line of irnmunoprecipitate 
indicates purity of preparations. 
The AFP eluates obtained in this manner was quantitated by 
standard immunodiffusion techniques employed at the YNHH Clinical 
Immunology Lab and was found to contain approximately 35 micrograms 
AFP per milliliter. 
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Production of Antiserum 
Anti-AFP serum used in this study was produced in four 
laboratory rabbits over a two month period of time. The initial 
sensitization was accomplished by injection of 1 ml of a suspension 
of purified AFP in Complete Freunds Adjuvant into the foot pads 
and dorsal fat pads of the four rabbits. The injections were 
repeated twice more at four week intervals with 1 ml of a 
suspension of purified AFP in Incomplete Freunds Adjuvant, The 
rabbits were bled 10 ml on four separate occasions by intracardiac 
puncture at approximately three week intervals after the initial 
sensitization. After each bleeding, the sera obtained were 
tested for immuncprecipitation of normal human serum and of AFP. 
The antisera continued to produce specific immunoprecipitation of 
AFP (Figure II) with no precipitation of normal human serum 
components, and were utilized in the isolation of additional AFP 




Specificity of Rabbit Anti-AFP Sera 
Figure II. Large center well contains purified AFP. Small wells 
contain one of four different AFP-specific antisera. 
Counterimmunoelectrophoresis 
All specimens were tested for the presence of detectable 
AFP by a well established technique of counterimmunoelectrophoresis 
(CEP) routinely used in the YNHH Clinical Immunology Lab. The 
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technique involves use of a 3 X 4 inch glass plate coated with 2% 
Agarose in Barbital Buffer (pH 7.4). Serum with a previously 
determined quantity of AFP (66 piq/ml) was diluted to an AFP 
concentration of 300 nanograms per milliliter and was included on 
each CEP plate. This control was readily detectable as being 
positive for AFP, thus establishing a sensitivity for the technique 
of at least 300 nanograms per milliliter. Current re-evaluation of 
the CEP technique suggests that its sensitivity may actually be 
in the region of 150 nanograms per milliliter. This re-evaluation, 
however, is as yet incomplete and so, for the current study, the 
300 nanogram figure was employed as the lower limit of sensitivity 
for the CEP. 
Radioiodination of AFP 
Iodination of purified AFP was accomplished by a modification 
of the technique described by Greenwood and Hunter.137 Twenty 
microliters of 0.2 M phosphate buffer (pH = 7.4) was added to 
200 microliters (7 micrograms) of AFP. To this was added 10 microliters 
of 5 nCi/ml Na^^l in dilute NaOH solution, pH 8-11 (The Radio¬ 
chemical Centre, Amersham, England). Five microiiters of 0.05 M 
phosphate buffered saline (PBS), pH 7.4 containing 25 micrograms of 
chloramine-T was immediately added. After approximately 10 
seconds* mixing, lO microiiters of PBS containing 150 micrograms of 
sodium metabisuiphite, followed by 20 microiiters of PBS containing 




^1 into AFP was determined by gel filtration on P-30 polyacrylamide 
gel (1 X 20 cm column)* which was used to separate the labeled 
protein from excess radioiodine. The labeled AFP was collected 
in six-drop fractions into plastic scintillation tubes (Falcon 
16 X 25 mm tubes) containing 0«1 ml of 0.05 M PBS. The degree of 
radioactivity in the peak AFP-containing fraction was determined by 
a Nuclear-Chicago automatic gamma sample counter. 
In order to remove any rabbit protein (remaining from the 
AFP isolation process) which might have been randomly iodinated 
along with the AFP, the iodinated protein was treated with a 
pellet of glutaraldehyde-polymerized donkey anti-rabbit serum in 
the manner described for anti-normal human serum in the section 
on "Isolation of AFP*" After removal of the pellet., measurable 
radioactivity in the labeled protein sample was found to have 
decreased by approximately 30%, indicating a specific removal of 
■*-2^I-labeled rabbit protein, and/or a non-specific absorption of 
protein which may have been damaged in the course of iodination. 
The immunoreactivity of the labeled AFP was then determined. 
In order to do this, the percentage of radioactive AFP precipitated 
by a l/2000 dilution of the anti-serum used in the final radio¬ 
immunoassay was compared with the precentage precipitated by the 
same dilution of normal rabbit serum (non-immune). To 20 
microliters of protein carrier (1% Bovine serum albumin in PBS, 
pH 7.4) were added 20 microliters of -*-^5l-laheled AFP (diluted 
with 1% BSA so as to contain 10,000 counts per minute), and 20 
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microliters of either 1/2000 rabbit anti~AFP serum or l/2000 
normal rabbit serum. After adequate mixing, this was allowed to 
stand at 4°C for 20 hours. At this time, the samples were spun 
in a Sorvall RC2-B refrigerated centrifuge for 20 minutes at 
15000 xpm and 5°C. The supernatant and precipitate, were then 
separated, with each being placed in a separate Falcon 
scintillation tube. The radioactivity present in each tube was 
then counted for one minute by a Nuclear-Chicago automatic gamma 
sample counter. The percentage of the total radioactivity for 
each sample which was present in the immunoprecipitate was then 
calculated. The presence of 95% or more of the total radioactivity 
in the supernatant of the normal rabbit serum samples was considered 
acceptable, with the remaining 5% or less remaining in the original 
reaction vial due to nonspecific effects. Immunoprecipitation of 
25% or more of the labeled AFP by the immune serum was considered 
as evidence that the radioactive protein was sufficiently 
immunoreactive for use in radioimmunoassay. 'I-labeled AFP 
showing less than 25% binding was considered adequate for use in 
immunoautoradiography. 
Immunoautoradiography 
Eighty-four (all CF sera and a random selection of 14 normals 
and 48 heterozygotes) of the ninety-five specimens collected for 
this study were tested for the presence of detectable AFP by a 
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technique of immunoautoradiography. A similar technique employed 
by Abelev et al.^8 was able to detect AFP in the sera of pregnant 
women and patients with hepatitis. Six standard dilutions of AFP 
positive fetal serum (previously quantitated in triplicate at 
50 micrograms per milliliter) were made so as to contain 150, 100, 
70, 50, 30, and 20 nanograms of AFP per milliliter. These dilutions 
were made by adding appropriate amounts of AFP-negative (by 
Counterimmunoelectrophoresis) normal human serum and enough 
1 pq 
I-labeled AFP to provide 20,000 cpm in 25 microliters of the 
final mixture. In order to remove any possible traces of AFP, 
the normal human serum used for dilution had previously been 
incubated with a pellet of glutaraldehyde-polymerized specific 
anti-AFP serum in a manner identical to that described for the 
purification of AFP with a pellet of polymerized anti-whole human serum 
(see "Isolation of AFP," p. 31). It was determined by use of a 
normal rabbit serum control that such a pellet was able to 
absorb on the order of 100 nanograms of AFP (or 50 nanograms per 
milliliter for the 2.0 milliliter samples of normal human 
serum processed for dilution), which should well represent virtually 
all of the AFP present in a sample of normal human serum (Ruoslahti 
and Sepp^l^'had found levels of AFP from 1.5-16 nanograms 
per milliliter in specimens of normal human serum). This determination 
was made by adding a known amount of AFP (from a fetal serum source) 
to whole normal rabbit serum, incubating this sample with a pellet 
of polymerized anti-AFP serum, and then quantitating by 

radioimmunoassay techniques the amount of decrease in AFP. 
Also prepared were an AFP-positive control quantitated at 
94 nanograms AFP per milliliter and a negative control containing 
only the normal human serum used for dilution with no unlabeled 
AFP added. To these controls and to each of the sera tested was 
added enough labeled AFP to provide 20,000 cpm in 25 microliters. 
The AFP dilutions (to provide a standard curve for quantification 
of unknown samples), the two controls., and thirteen unknown samples 
were set up in duplicate on each immunoautoradiography plate. 
The plates consisted of 3 X 4 inch glass slides coated with 15.0 
milliliters of Special Noble Agar prepared in normal saline and 
containing 4,0 microliters of anti-AFP serum per milliliter (for 
immunoprecipitation of any AFP present). Forty-two wells, each 
holding 25 microliters of sample, had been cut into the agar. The 
plates were allowed to stand in moist plastic chambers at room 
temperature for 43 hours. They were then immersed in normal 
saline and allowed to wash at room temperature for another 48 hours. 
At that time they were removed from the saline and wrapped in a 
single layer of Saran Wrap. In a darkroom, 3X4 inch pieces of 
Kodak P.P-14 Medical X-ray film were placed in contact with the 
agar coated side of each plate, and they were appropriately 
stored so as to avoid exposure to light. After one week, the 
exposed sheets of film were developed using Kodak Dental X-ray 
Developer, and then contact printed onto Agfa (Grade 6) High Contrast 
photographic paper. The diameter of the circle of exposure for 
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each well was measured with an average of the diameters of 
duplicate wells being taken. Values to provide standard curves 
from which the values of unknown specimens could be estimated. 
Radioimmunoassay (RIA) 
The technique employed for RIA was a non-equilibrium one 
in which addition of ^^I-labeled AFP was made after the test 
samples had been incubated with the anti-AFP antiserum for 
48 hours. The double antibody technique employed by Ruoslahti 
and Sepp&lS^^ and by Purves and Purves^^ was considered. This 
technique* however (attempted with goat anti-rabbit serum)* 
showed no advantage in the ability to precipitate anti-AFP 
serum bound I-labeled AFP over (NH^)^0/j in our hands. We 
therefore elected to use the ammonium sulfate as it was more 
readily available. Twenty microliters of a 1% solution of BSA 
in PBS (pH 7.4) were included in each sample as a protein carrier. 
Early experiments had exhibited a problem with adherence of 
labeled AFP to the sides of the reaction vessel. This was 
eliminated by inclusion of the BSA. 
In preparation for the radioimmunoassayfl the appropriate 
dilution of antiserum for use was determined. Anti-AFP serum 
dilutions of l/lOOO* 1/2000* 1/3000* l/4000s and l/8000 were 
prepared with PBS (pH 7.4). Twenty microliters of each dilution 
were added in duplicate tubes (Fischer polyethylene centrifuge 
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tube Sj 1 ml capacity) containing 20 microliters of a 1% solution 
of BSA in PBS (pH 7.4). To this was added 20 microliters of 
I-labeled AFP diluted with 1% BSA so as to give 3000 counts per 
minute. The tubes were mixed with a Vortex mixer and then 
incubated at 37°C for one hour. They were then refrigerated at 
4°C for 20 hours* after which time 0.2 milliliters of a 43.5% 
solution of ammonium sulfate were added. After mixing* the tubes 
were again stored at 4°C for 20 hours. They were then spun 
at 15000 rpms 5°C in a Sorvall RC2-B automatic refrigerated 
centrifuge for 20 minutes. The supernatant was removed by 
Pasteur pipet and the radioactivity in both supernatant and 




















Antiserum Dilution (XlCT^) 
The antibody concentration binding at least 25% of the precipitable 
counts* in this case 1/2000* was selected for use in the assay. 
In order to obtain a standard inhibition curve from which to 
determine the level of AFP in unknown samples, standard dilutions 
of AFP-positive fetal serum (previously quantitated in triplicate) 
were made using the absorbed normal human serum described earlier as 
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diluent (See ".Immunoautoradiography8" p. 38). Seven such dilutions 
were made so as to contain 15* 259 50, 75, 100, 150, and 200 
nanograms of AFP per milliliter, respectively. Three standard 
curves were set up in duplicate, one with each of the three 
batches of unknown sera which wrere run. In each 1 ml centrifuge 
tube, 20 microliters of AFP dilution and 20 microliters of a 
1/2000 dilution of anti-AFP serum in 1% ESA were added to 20 
microliters of 1% BSA in PBS (pH 7.4). This was thoroughly 
mixed, incubated for one hour at 37°C and then stored for 48 hours 
at 4°C. At this time 20 microliters of ^^I-labeled AFP diluted 
in 1% BSA so as to contain 3000 counts per minute were added* The 
samples were again mixed, incubated at 37°C for one hour, and 
stored at 4°C for 24 hours, A 0*2 milliliter quantity of a 47.5% 
solution of ammonium sulfate PBS (pH 7,4) was then added. The 
samples were mixed and stored at 4°C for 24 hours. They were then 
spun in the Sorvall P.C2-B for 20 minutes at 15000 rpm, 5°C« The 
supernatant was removed by Pasteur pipet. Supernatant and immuno- 
precipitate were placed in separate Falcon 16 X 25 mm tubes for 
counting on a Huclear-Chicago automatic gamma counter. The results 
were plotted on Semi-Log graph paper (#cpin in precipitate///cpm in 
supernatant or BOUNd/fPyEE v_s Concentration of AFP in ng./ml). 
Each series included two control tubes in duplicate. One control 
contained the same processed normal human serum used for dilution, 
but had no added "cold" AFP ("Trace Tube"). The second control 
also contained normal human serum without added AFP, but the anti-AFP 
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serum was also omitted from this tube. The counts observed in the 
precipitate of this tube represent non-specific radioactivity, or 
the Percent of Damage for the assay. This Percent of Damage was 
subtracted from the precipitated counts for both the standard curve 
and unknown samples prior to calculating the “/? ratio and plotting 
these values. The ®/f values appearing in the graphs therefore 
represent the corrected ®/F ratios. 
The undiluted sera of CF patients, heterozygotes, and normals 
were tested in duplicate using 20 microliter samples as in the case 
of the AFP dilutions. The setting up and processing of these 
specimens was identical to those for the standard inhibition curve 
save for the substitution of the unknown samples in place of the 
AFP dilutions. All samples were thawed for the first time 





None of the ninety-five sera tested in this study showed 
any visible evidence of immunoprecipitation with anti-AFP serum 
on counterimmunoelectrophoresis. The positive control (containing 
300 nanograms AFP per milliliter) included on each plate was 
clearly distinguishable as positive for AFP* a single line of 
immunoprecipitation being easily visible. 
Immunoautoradiography 
) 
The standard curve used to estimate the values of AFP concentration 
in unknown samples and to establish the lower limits of sensitivity 
of the technique is presented in Figure IV. It was found that the 
sensitivity of immunoautoradiography technique was approximately 
70 ng/ml in our hands. AFP concentrations above this value were 
readily distinguishable from each otherj while those below 
70 ng/ml produced rings of exposure of virtually identical diameter. 
Ring diameters for all standard curve dilutions and all unknown 
sera were measured to the nearest 0.5 mm. It was found that none of 
the 84 sera tested by this technique produced a ring diameter which 
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of the contact prints from which the determinations were made 5s 
presented in Figure V. This particular plate contains 13 CF sera 
in duplicate in the lower four rows. Included on each plate was 
an AFP-positive controls previously quantitated at 9A ng/ml by 
gel immunodiffusion techniques. The observed ring diameter for 
these samples was measured at 11 mms which, when squared and 
plotted on the standard curve, showed a value of 95 ng/ml, indicating 
the accuracy of the immunoautoradiography technique. 
FIGURE V. Immunoautoradiography Samples 
COLUMNS 
Figure V. All samples are presented in duplicate. Measurements 
made were of the horizontal diameter of each ring. 
ROW 1 & 2: AFP dilutions of 150, 100, 70, 50, 30, 
and 20 ng/ral in COLUMNS 1-7. COLUMN 7 contains AFP- 
positive control (9d ng/ml). ROW 3 & A: COLUMN 1 
contains AFP-negative normal human serum. COLUMNS 2-7 





1. Standard Inhibition Curve 
The standard inhibition curves from three separate trials 
are presented in Figure VI* plotted on a semi-logarithmic scale. 
The relationship between the concentration of AFPS and the 
inhibition obtained is linear from 25-100 ng/ml, This* then* 
represents the lower limit of sensitivity (25 ng/ml)* and the 
working range (25-100 ng/ml) of the assay. Values for AFP 
concentrations less than 25 ng/ml and greater than 100 ng/ml 
cannot be assigned. 
2. Serum Samples 
The results of AFP concentration measurements in the unknown 
sera are depicted in Table II. Log means are presented in addition 
to the arithmetic means so that the results can be compared directly 
to those of Chandra et al«^ Of the 22 CF sera tested* 17 had 
AFP values in the < 25 ng/ml range; 8 had values in the measurable 
range (Range = 26-32; X = 28.4); none had values >100 ng/ml. 
Thirty-two of 53 parents had AFP values of <25 ng/rnl; 20 had 
measurable values (Range = 25-53; 5< = 28.8); and one had a value 
>100 ng/ml. Both siblings tested had AFP values in the <25 ng/ml 




















8 had values between 25 and 100 ng/rnl (Range = 25-28; 2 = 26.6); 
and none had values >100 ng/ml. The heterozygote serum which 
was measured at >100 ng/rnl was re-evaluated by counterimmunoeiectro- 
phoresis and OuchterlBny gel diffusion and again proved negatives 
suggesting that if this is a true elevations the actual value should 
fall between 100 and 300 ng/ml. 
Statistical analysis (Fisher's "Exact Test") evaluating all 
possible group pairs failed to demonstrate any statistically 










No. X L.M. MED. RANGE 
M 15 
PATIENTS 22 F 7 17 5 23.4 
28.3 
±1.1 28 26-32 0 
M li 
CONTROLS 18 F 7 10 8 26.6 
26.6 
±1.0 26.5 25-28 0 
M 0 
SIBLINGS 2 F 2 2 0 — ----- 0 
M 20 
PARENTS 53 F 33 32 20 28.8 
23.3 
±1.1 27.6 25-53 1 
X = Arithmetic Mean; L.M. = Log Mean - Standard Error of Mean; 
MED. = Median. 

DISCUSSION 
The original report by Chandra et al.^ of an elevated level 
of AFP in children with CF seemed based on a reasonable premise. 
The involvement of the liver in CF has been well documented with 
localized foci of biliary obstruction and fibrosis commonly found 
at autopsy., even in infants. In some patients, particularly 
those in their teens, these changes progress and cause a distinctive 
type of multilobular biliary cirrhosis with large irregular nodules. 
The relationship between non-malignant liver disease and elevated 
1 OO 1 OS 
AFP levels has been documented, * ' and it therefore seemed 
entirely possible that AFP levels might well be elevated in CF 
patients with their chronic liver involvement. The CF Gene could 
well affect normal maturation processes so as to result in the 
persistence of embryonic cell lines capable of AFP synthesis, 
and to make the liver more susceptible to damage as Chandra lias 
3 
suggested. The current study has, however, by three separate 
systems of measurement characterized by differing levels of 
sensitivity, failed to support the results of Chandra and his 
co-workers. Counterimmunoelectrophoresis, easily able to 
demonstrate the presence of AFP concentrations as low as 300 ng/ml 
(and possibly as low as 150 ng/ml), failed to detect the presence 
of AFP in any of the samples tested. This already placed the 




those reported by Chandra et al.s and indicated that they were 
certainly lower than 300 ng/ml, Though clearly lower than the 
levels reported, the possibility still existed that CF and heterozygote 
serum AFP concentrations might still fall in an elevated range. 
This range of possible elevation was further decreased by use of 
immunoautoradiography. The lower limit of sensitivity of this 
technique having been established at 70 ng/ml by use of a 
standard curve, it was found that none of the samples tested fell in 
the range above 70 ng/ml. An AFP-positive control (previously 
quantitated at 94 ng/ml) was included on each of the autoradiography 
plates. Plotting the square of the diameter measured for this 
sample (diameter ^ = 121) yielded a value of 95 ng/ml from the 
standard curve, indicating the acceptable accuracy of the technique. 
Radioimmunoassay with a sensitivity limit of 25 ng/ml 
established that all but two samples tested fell in the normal 
range. The sample whose AFP concentration fell in the greater than 
100 ng/ml range was retested by counterimmunoelectrophoresis, and 
was again negative. This suggests that if the radioimmunoassay 
estimation is correct, the subject's serum AFP concentration lies 
somewhere between 100 and 300 ng/ml. The subject, an obligate 
heterozygote, continues to enjoy good health with no evidence of 
chronic disease. Due to a limited supply of radio-labeled AFP, this 
subject's serum was unfortunately one of eleven sera which were 
randomly eliminated from the group evaluated by immunoautoradiography. 
We are therefore unable to confirm the observation of an elevated 
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AFP concentration by this technique. 
The second elevated serum was quantitated at 53 ng/ml. 
This value is quite similar to that of 50 ng/ml described by 
Ruoslahti and Sepp&lh^' in a normal (non-carrier of CF) healthy 
24 year old male with no detectable liver disease or history of 
any other chronic disease. The subject in this study3 though 
a heterozygote, is equally healthy. Occasional elevated values 
in clinically healthy subjects carry an unknown significance 
at this time. While they may well bespeak the presence of some 
underlying defect or subclinical disease entity, they must be 
regarded as normal variants until such a relationship can be 
demonstrated. 
The range of AFP concentrations observed among normals in 
this study ( 25 to 28 ng/ml) exhibits a slightly higher upper 
limit than that of some experimenters^1^ (up to 25 ng/ml), but 
is well within the range observed by others^^ (3-51 ng/ml). It 
seems clear that there is considerable room for normal variation 
in the AFP concentrations measured by sensitive techniques such as 
radioimmunoassay. The mean and median values for the samples 
which could be accurately quantitated in our study are both higher 
than those observed in other studies measuring AFP by the same 
means. The reason for this is that the sensitivity limits of our 
assay were such that we were unable to accurately quantitate 
those values which fell in the less than 25 ng/ml range. Thus, our 
mean and median values represent only those AFP concentrations which 
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fell in the 25-100 ng/ml range. It is expected, from the number of 
values which fell below 25 ng/ml, that accurate quantification of 
these lower values would have resulted in mean and median values 
more closely resembling those of other experimenters. 
Vie were somewhat disappointed with the narrow working range 
(25-100 ng/ml) of sensitivity of our assay. Though we were able 
to compensate for limitations on the upper end of the range by 
use of the counterimmunoelectrophoresis and immunoautoradiographic 
techniques, it would have been desirable to have had a lower limit 
of sensitivity in the region of 1-2 ng/ml, though Ruoslahti and 
SeppSlH have reported a sensitivity threshold of 250 picograms/ml,^J 
The limiting factor appears to have been the inability to achieve 
high enough antibody titers in the two month period of time over 
which the rabbits were immunized. The specificity of the antibody, 
despite its low titer, appeared to be high as evidenced by specific 
immunoprecipitation seen on gel immunodiffusion and Immunoelectro¬ 
phoresis. Evidence of the relatively low antibody titer is provided 
in Figure III which demonstrates that specific binding by our 
antibody falls off considerably in going from a l/2000 to a 1/3000 
dilution. Binding is almost non-existent at a l/SOOO dilution, 
Ruoslahti and SeppcllS-LO'J in contrast, report near maximal binding 
at an antiserum dilution of 1/25000, with significant binding still 
occurring with the antiserum diluted 1/3,000,000. This was achieved 
with a sheep antiserum produced by 5 months' immunization. Because 
of the low antibody titer, we were also' unable to employ dilutions 
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of our test sera since this would have placed our Working range in 
the region of the sensitivity of the autoradiography technique. 
Despite these problems, however, our sensitivity threshold is 
almost the same as the 20 ng/ml level achieved by Purves and Purves^ 
who also used undiluted test sera, though their working range was 
broader (20**1000 ng/ml). 
Perhaps our greatest disappointment was in the fact that we 
were unable to provide evidence in support of the usefulness of 
serum AFP levels as a marker for the CF heterozygote state. 
We were somewhat concerned when, after having begun our study, 
we noted the negative results reported by the three British 
investigators, but. remained hopeful that we migru. see 
positive results in this study until the time that our own data 
became final. 
The reason for the contradictory findings is unclear. In 
view of the fact that the published data suggesting the 
correlation between AFP and CF has come from sources on this side 
of the Atlantic while those denying it come from Europe, it is 
conceivable that there is a basic difference between CF in the 
two settings. We know of no such differences, and our data would 
seem to tip the scales against such a hypothesis. Differences 
in therapeutic regimes seem unlikely as the cause for elevated 
AFP levels as elevations were reported in heterozygotes who 
presumably receive no such treatment. 
It is conceivable that Chandra’s assay was measuring the 
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presence of some factor other than AFP, Confirmation that AFP 
was indeed the factor whose levels were measured could be made by 
use of immunoabsorbents in the manner described by Ruoslahti and 
135 
Sepp’llS,' ' These experimenters absorbed AFP from test samples 
containing measurable amounts (by radioimmunoassay) of AFP by means 
of a glutaraldehydepolymerized specific anti-AFP serum in the manner 
described earlier in this paper. The test sera (with AFP removed) 
were re-tested by radioimmunoassay for the presence of AFP, Absorbed 
AFP was freed from the glutaraldehyde pellet by acid dissociation 
and these samples were then re-tested for AFP content. While the 
same process could have been employed in our study, the antiserum 
initially used by us for AFP isolation has been reliably used in the 
past for AFP detection and quantification, making it quite unlikely 
that we might have isolated a serum factor other than AFP. In 
addition, it would seem at this time that the burden of proof is 
upon Chandra and his group. Should Chandra’s antiserum prove 
to be binding some factor other than AFP, this would still be 
a highly significant finding as any measurable difference able 
to reliably differentiate CF patients and heterozygotes from normals 
would be a- noteworthy achievement. 
In conclusion, our results lend support to those of other 
investigators who have failed to find evidence that the measurement 
of serum AFP concentrations might be used to identify asymptomatic 
carriers of the Cystic Fibrosis Gene. The need for a reliable method 
for heterozygote detection in this disease is a critical one in view 
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of its notably high incidence. Without such a method* efforts 
to lower the incidence of cystic fibrosis by genetic counseling 
will remain virtually impossible. 
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